News
GLP-1 Shortage and Supply News
Latest — updated August 10, 2026
Supply-chain status:
No shortage, no bulk pathway: the supply logic inverts
With both molecules long off the shortage list and the 503B exclusion pending, compounded supply narrows to patient-specific 503A channels — making named pharmacies and month-to-month billing the defensive defaults for any compounded program in 2026.
Monitored category — items publish only when newsworthy and sourced.
The shortage-and-supply category tracks official FDA drug-shortage status for GLP-1 products and its implications for compounding. Shortage status is a regulatory determination with dates; we distinguish it clearly from marketing claims about availability.
What we watch in this category
- FDA shortage list additions and resolutions
- Manufacturer supply statements
- Compounding implications of resolved shortages
- Date distinctions between products and doses
Primary sources monitored
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.